Scientists explored selectively blocking the CYP3A4 protein responsible for breaking down large swaths of approved drugs, providing a way to improve drug efficacy.

Label updates include simplified twice-yearly echo monitoring for eligible CAMZYOS patients in the maintenance phase and expanded patient eligibility with reduced contraindication ...

Camzyos is an oral, selective allosteric and reversible inhibitor of cardiac myosin. It was approved in April 2022 for the treatment of adults with symptomatic New York Heart Association (NYHA) class ...

The drug is cleared by cytochrome P450 (CYP ... Blood levels of eplerenone are increased by inhibitors of CYP3A4, such as ketoconazole and saquinavir. About 50% is bound by plasma protein.

SaveHealth assesses the relative benefits of Zoloft vs. Lexapro, comparing their usage, effectiveness, tolerability, ...

When a medication works right, it boosts your health or helps you feel better. But a drug can bring on problems if it doesn't mix well with something else you put into your body, like another ...

Princeton: Bristol Myers Squibb has announced that the U.S. Food and Drug Administration (FDA) has updated the U.S.